Grants and Contracts Details
Description
VCID encompasses a spectrum of neurovascular changes ranging from chronic, progressive, and
dementia-associated small vessel diseases (SVD) of the brain to the often-catastrophic damage
following acute stroke. VCID clinically presents similar to other dementia diagnoses, but with a high
prevalence of cardiovascular (CV) risk factors (e.g. hypertension, dyslipidemia). Besides drug
therapies treating underlying cardiovascular disease, lifestyle interventions that increase physical
activity also reduce the risk for VCID by minimizing neurovascular injury and improving cognition.
Unfortunately, evidence linking CV and exercise interventions to the prevention of cognitive decline is
inconclusive, nor are biomarkers available to determine the efficacy of pre-dementia lifestyle
interventions. This American Heart Association Career Development Award (CDA) will utilize banked
plasma and neuroimaging from subjects enrolled in the NIH-funded trial “Risk Reduction for
Alzheimer’s Disease (rrAD).” This phase II randomized controlled trial will determine the independent
and combined effects of Intensive pharmacological Reduction of Vascular Risk factors (IRVR; i.e.
blood pressure, lipids) and aerobic exercise (Ex) on cognitive function in cognitively normal older
adults with memory complaints or a family history of AD and who have hypertension/dyslipidemia.
Participants were randomized into two-year interventions (IRVR, Ex, IRVR+Ex, and a control arm of
standard care (SC)) with plasma and neuroimaging collected at baseline and yearly. Longitudinal
rrAD samples will be used to test the hypothesis that 1) ICAM-1, GFAP, and Nfl expression in
extracellular vesicles (EV) can predict changes in neuroimaging (cerebrovascular reactivity (CVR)
and white matter hyperintenisities (WMH)), 2) IRVR+Ex plasma-derived EVs are protective following
hypoxia, compared to S.C, in cells of the neurovascular unit, and 3) the neurobiological profile of
IRVR+Ex EVs express increased markers of neuroplasticity, blood brain barrier, and growth factors
compared to S.C EVs. This grant will identify biomarkers that track effective lifestyle interventions to
delay dementia in high-risk individuals with CV risks prior to cognitive decline.
Status | Finished |
---|---|
Effective start/end date | 4/1/23 → 3/31/24 |
Funding
- American Heart Association: $77,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.